Literature DB >> 11507655

Changes in cerebral glucose metabolism and visuospatial capability in hypogonadal males under testosterone substitution therapy.

M Zitzmann1, M Weckesser, O Schober, E Nieschlag.   

Abstract

Genders differ concerning abilities of spatial cognition; positive associations of testosterone levels with corresponding scores have been reported, as well. We addressed the question whether there is a testosterone-susceptible area within cerebral structures previously described to be involved in mental rotation. Using F-18-deoxyglucose (FDG)-positron emission tomography (PET), we studied cerebral glucose metabolism during a standardized 3-dimensional mental rotation task in 6 right-handed men with hypogonadotropic hypogonadism before and under testosterone substitution therapy. Under elevated testosterone levels, enhanced cerebral glucose metabolism during mental rotation was observed in the 4 subjects with improved visuospatial capability. Areas involved were previously demonstrated to be activated by such tasks in eugonadal men.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11507655     DOI: 10.1055/s-2001-16351

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  10 in total

Review 1.  [Therapy of male hypogonadism].

Authors:  M Zitzmann
Journal:  Internist (Berl)       Date:  2008-05       Impact factor: 0.743

2.  Effect of Testosterone Replacement Therapy on Cognitive Performance and Depression in Men with Testosterone Deficiency Syndrome.

Authors:  Hyun Jin Jung; Hong Seok Shin
Journal:  World J Mens Health       Date:  2017-01-23       Impact factor: 5.400

3.  Nandrolone Supplementation Promotes AMPK Activation and Divergent 18[FDG] PET Brain Connectivity in Adult and Aged Mice.

Authors:  N R Strogulski; A Kopczynski; V G de Oliveira; R B Carteri; G Hansel; G T Venturin; S Greggio; J C DaCosta; M A De Bastiani; M S Rodolphi; L V Portela
Journal:  Neurochem Res       Date:  2022-04-12       Impact factor: 3.996

Review 4.  [Hypogonadism in the elderly man. Reliable diagnosis and therapy].

Authors:  M Zitzmann; E Nieschlag
Journal:  Internist (Berl)       Date:  2003-10       Impact factor: 0.743

Review 5.  Onset of effects of testosterone treatment and time span until maximum effects are achieved.

Authors:  Farid Saad; Antonio Aversa; Andrea M Isidori; Livia Zafalon; Michael Zitzmann; Louis Gooren
Journal:  Eur J Endocrinol       Date:  2011-07-13       Impact factor: 6.664

Review 6.  Sex steroid hormones and brain function: PET imaging as a tool for research.

Authors:  R Moraga-Amaro; A van Waarde; J Doorduin; E F J de Vries
Journal:  J Neuroendocrinol       Date:  2018-02       Impact factor: 3.627

7.  Changes in resting-state measures of prostate cancer patients exposed to androgen deprivation therapy.

Authors:  Julio Plata-Bello; Ana Plata-Bello; Yaiza Pérez-Martín; David López-Curtis; Silvia Acosta-López; Cristián Modroño; Tomás Concepción-Massip
Journal:  Sci Rep       Date:  2021-12-02       Impact factor: 4.379

8.  A Personal Prospective on Testosterone Therapy in Women-What We Know in 2022.

Authors:  Gary S Donovitz
Journal:  J Pers Med       Date:  2022-07-22

9.  Changes in neuronal activation patterns in response to androgen deprivation therapy: a pilot study.

Authors:  Monique M Cherrier; Paul R Borghesani; Amy L Shelton; Celestia S Higano
Journal:  BMC Cancer       Date:  2010-01-04       Impact factor: 4.430

Review 10.  Clinical significance of androgen secretion disorders in men with a malignancy.

Authors:  Pawel J Wiechno; Grazyna M Poniatowska; Wojciech Michalski; Jakub Kucharz; Malgorzata Sadowska; Joanna Jonska-Gmyrek; Karol Nietupski; Joanna Rzymowska; Tomasz Demkow
Journal:  Med Oncol       Date:  2017-06-01       Impact factor: 3.064

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.